Document:

Exhibit
10.14

 

FIRST
AMENDMENT TO LICENSE AGREEMENT

 

THIS
FIRST AMENDMENT TO LICENSE AGREEMENT made this 3rd day of July 2018.

 

TEXAS
MEDICAL CENTER (“Licensor”), and B1OLIFE4D INC., a Delaware C-Corporation (“Licensee”) are parties
to a certain License Agreement (“License”) dated April 3, 2018 with respect to premises identified as Lab Bench J-251-D located
at 2450 Holcombe Boulevard, Houston, Texas 77021- 2040.

 

	 	A.	The
    Licensee wishes to modify their footprint in JLABS @ TMC and Licensor has agreed to accommodate this request.

 

NOW,
THEREFORE, in consideration of the foregoing, which is incorporated herein by reference, for mutual promises contained herein, and for
other good and valuable considerations, the receipt and sufficiency of which are hereby acknowledged, Licensor and Licensee hereby agree
as follows:

 

	 	1.	Effective
    July 15th, 2018, Licensee shall no longer have access to Lab Bench J-251-D.

 

Effective
July 15th, 2018, Licensee shall have access to Lab Bench J-25 l-P and J-251-Q.

 

	 	2.	Section
    2.1 of the License shall be amended to reflect an increase in the License Fee in the amount of $1,000.00 for a total License Fee
    in the amount of $2,000.00 per month.
	 	 	 
	 	3.	Section
    2.5 of the License shall be amended to reflect that on or before the Effective Date, Licensee shall deposit with licensor the additional
    amount of $2,000 for a total Security Deposit of $4,000.00.
	 	 	 
	 	4.	Except
    as amended by this 1st Amendment, all other terms of the License shall remain in full force and effect.

 

(signatures
on the following page)

 

    	 

    	 

    

 

IN
WITNESS WHEREOF, Licensor and Licensee have caused their duly authorized representatives to execute this 1st Amendment as of the date
first written.

 

	 	LICENSOR:
	 	 
	 	TEXAS
    MEDICAL CENTER
	 	 	 
	 	By:	/s/
    William F. McKeon
	 	Name: 	William
    F. McKeon
	 	Title:	President
    and CEO
	 	 	 
	 	LICENSEE:
	 	 
	 	BIOLIFE4D
    INC.
	 	 	 
	 	By:	/s/
    Steven Morris 
	 	Name:	Steven
    Morris
	 	Title:	CEOExhibit
10.15

 

SECOND
AMENDMENT TO LICENSE AGREEMENT

 

THIS
SECOND AMENDMENT TO LICENSE AGREEMENT made this 29th day of October 2018.

 

TEXAS
MEDICAL CENTER (“Licensor”), and BIOLIFE4D INC., a Delaware C-Corporation (“Licensee”) are parties
to a certain License Agreement (“License”) dated April 3, 2018 with respect to premises identified as Lab Bench J-251-P and
J-251-Q located at 2450 Holcombe Boulevard, Houston, Texas 77021-2040.

 

	 	A.	The
Licensee wishes to modify their footprint in JLABS @ TMC and Licensor has agreed to accommodate this request.

 

NOW,
THEREFORE, in consideration of the foregoing, which is incorporated herein by reference, for mutual promises contained herein, and for
other good and valuable considerations, the receipt and sufficiency of which are hereby acknowledged, Licensor and Licensee hereby agree
as follows:

 

	 	I.	Effective
November 1st, 2018, Licensee shall no longer have access to Lab Bench J-251-P and J- 251-Q.
	 	 	 
	 	2.	Effective
    November 1st, 2018, Licensee shall have access to Lab J-307.
	 	 	 
	 	3.	Section
    2.1 of the License shall be amended to reflect an increase in the License Fee in the amount of $2,000.00 for a total License Fee
    in the amount of $4,000.00 per month.
	 	 	 
	 	4.	Section
    2.5 of the License shall be amended to reflect that on or before the Effective Date, Licensee shall deposit with licensor the additional
    amount of $4,000 for a total Security Deposit of $8,000.00.
	 	 	 
	 	5.	Except
    as amended by this 2nd Amendment, all other terms of the License shall remain in full force and effect.

 

(signatures
on the following page)

 

    	 

     

    

 

IN
WITNESS WHEREOF, Licensor and Licensee have caused their duly authorized representatives to execute this 2nd Amendment as
of the date first written.

 

	 	LICENSOR:
	 	 
	 	TEXAS
    MEDICAL CENTER
	 	 	 
	 	By:	/s/
William F. McKeon
	 	Name:	William
F. McKeon
	 	Title:	President
and CEO
	 	 	 
	 	LICENSEE:
	 	 
	 	BIOLIFE4D
    INC.
	 	 	 
	 	By:	/s/
Steven Morris 
	 	Name:
    	Steven
    Morris
	 	Title:
    	CEOEXhibit 10.16

 

THIRD
AMENDMENT TO LICENSE AGREEMENT

 

THIS
THIRD AMENDMENT TO LICENSE AGREEMENT made this 7th day of February 2022.

 

TEXAS
MEDICAL CENTER (“Licensor”), and BIOLIFE4D INC., a Delaware C-Corporation (“Licensee”) are parties
to a certain License Agreement (“License”) dated April 3, 2018 with respect to premises identified as Lab J-307 located at
2450 Holcombe Boulevard, Houston, Texas 77021-2040.

 

	 	A.	The Licensee wishes to modify their footprint in JLABS @ TMC
and Licensor has agreed to accommodate this request.

 

NOW,
THEREFORE, in consideration of the foregoing, which is incorporated herein by reference, for mutual promises contained herein, and for
other good and valuable considerations, the receipt and sufficiency of which are hereby acknowledged, Licensor and Licensee hereby agree
as follows:

 

		1.	Effective
                                            March 1st, 2022 Licensee shall have access to Office J-615.

 

		2.	Section
                                            2.1 of the License shall be amended to reflect an increase in the License Fee in the amount
                                            of $2,500.00 for a total License Fee in the amount of $6,867.20 per month.

 

		3.	Section
                                            2.5 of the License shall be amended to reflect that on or before the Effective Date, Licensee
                                            shall deposit with licensor the additional amount of $5,700 for a total Security Deposit
                                            of $13,700.

 

		4.	Except
                                            as amended by this 3rd Amendment, all other terms of the License shall remain
                                            in full force and effect.

 

(signatures
on the following page)

 

    	 

     

    

 

IN
WITNESS WHEREOF, Licensor and Licensee have caused their duly authorized representatives to execute this 3rd Amendment as
of the date first written.

 

	 	LICENSOR:
	 	 
	 	TEXAS
    MEDICAL CENTER
	 	 	 
	 	By:	/s/
    William F. McKean
	 	Name:	William
    F. McKean
	 	Title:	President
    and Chief Executive Officer

 

	 	LICENSEE:
	 	 
	 	BIOLIFE4D
    INC.
	 	 	 
	 	By:	/s/
    Steven Morris
	 	Name:	Steven
    Morris
	 	Title:	CEOExhibit
10.17

 

NOTE
PURCHASE AGREEMENT (JANUARY 2019)

 

This
Note Purchase Agreement (January 2019) (this “Agreement”) is by and between BioLife4D Corporation, a Delaware corporation
(the “Company”), and the undersigned subscriber (“Subscriber”). This Agreement shall be effective
as of the date that it has been executed by both the Company and Subscriber (the “Effective Date”). Capitalized terms
not otherwise defined in this Agreement shall have the meanings ascribed to them in Subscriber’s Note (as defined below).

 

RECITALS

 

WHEREAS,
the Company has authorized the sale and issuance of convertible promissory notes substantially in the form attached hereto as Exhibit
A (each, a “Note,” and collectively, the “Notes”), for the aggregate principal amount not in
excess of the Offering Maximum (as defined below), pursuant to the terms and conditions of this Agreement. This Agreement is one in a
series of agreements of like kind pursuant to which the offering contemplated hereby is conducted; and

 

WHEREAS,
Subscriber desires to purchase from the Company, and the Company desires to issue and sell to Subscriber, one or more Notes on the terms
and conditions set forth in this Agreement.

 

NOW,
THEREFORE, the Company and Subscriber hereby agree as follows:

 

1.
Definitions. The following capitalized terms shall have the following meanings as used herein:

 

“Affiliate”
means, with respect to Subscriber, (i) any other person or entity who, directly or indirectly, controls, is controlled by, or is under
common control with Subscriber, including without limitation any partner, member, manager, officer, director or employee of Subscriber
or any venture capital fund now or hereafter existing that is controlled by one or more general partners or managing members of, or shares
the same management company with, such person or entity or (ii) any child, parent, spouse or other member of the same household of Subscriber
who is a natural person referred to herein or a trust for the benefit of any such natural person.

 

“Consideration”
shall mean the purchase price paid by Subscriber for Subscriber’s Note(s) pursuant to this Agreement, as shown on the signature
page hereto, which shall be in an amount not less than $250,000, unless the Company agrees to accept less.

 

“Offering
Maximum” means an aggregate offering amount of up to $3,000,000.

 

2. Issuance
of Notes. In return for the Consideration paid by Subscriber, the Company shall sell and issue to Subscriber, a Note having an original
principal balance equal to the Consideration. Upon the execution of this Agreement, the Subscriber shall pay to the Company the Consideration
shown on the signature page hereto with respect to the Note and the Company shall issue a Note with respect to such Consideration. Each
Note shall be convertible into Conversion Securities pursuant to the express terms and conditions of Subscriber’s Note.

 

    	 

     

    

 

3. Closing.
The closing of the purchase and sale of the Note(s) to Subscriber shall take place at such time and place remotely via exchange of documents
and signatures. The following closing conditions shall apply:

 

3.1 To
subscribe for a Note, Subscriber must, and does hereby agree to, deliver to the Company: (i) a completed and executed counterpart of
the signature page to this Agreement, (ii) a certified or personal check, subject to collection, in an amount equal to the Consideration,
made payable to the order of the Company, or a wire transfer in such amount to such bank account as shall be designated by the Company,
and (iii) an executed Note.

 

3.2 The
closing may be held via an exchange of electronic copies of all closing documents. The Company may have more than one closing under this
Agreement; provided, however, that (i) the Company may not sell Notes totaling, in the aggregate, greater than the Offering Maximum and
(ii) the Company may not sell Notes after June 30, 2019.

 

4. Representations
and Warranties of Subscriber. In connection with the transactions provided for herein, Subscriber, hereby represents and warrants
to the Company that:

 

4.1 Authorization.
This Agreement constitutes Subscriber’s valid and legally binding obligation, enforceable in accordance with its terms, except
as it may be limited by (i) applicable bankruptcy, insolvency, reorganization, or similar laws relating to or affecting the enforcement
of creditors’ rights and (ii) laws relating to the availability of specific performance, injunctive relief or other equitable remedies.
Subscriber represents that it has full power and authority to enter into this Agreement.

 

4.2 Purchase
Entirely for Own Account. Subscriber acknowledges that this Agreement is made with Subscriber in reliance upon Subscriber’s
representation to the Company that the Note(s) and Conversion Securities (collectively, the “Securities”) will
be acquired for investment for Subscriber’s own account, not as a nominee or agent, and not with a view to the resale or distribution
of any part thereof, and that Subscriber has no present intention of selling, granting any participation in, or otherwise distributing
the same. By executing this Agreement, Subscriber further represents that Subscriber does not have any contract, undertaking, agreement
or arrangement with any person to sell, transfer or grant participations to such person or to any third person, with respect to the Securities.

 

4.3 Disclosure
of Information. Subscriber acknowledges that it has received all the information it considers necessary or appropriate for deciding
whether to acquire the Securities. Subscriber further represents that it has had an opportunity to ask questions and receive answers
from the Company and its representatives regarding the Company and its business and prospects. Subscriber acknowledges and agrees that
the only representations and warranties made by the Company to Subscriber are those made expressly in writing in Subscriber’s Note,
and that Subscriber is not relying on any other representations, warranties or promises in connection with the investment contemplated
herein. Without limiting the foregoing, Subscriber acknowledges that Subscriber’s decision to enter into this Agreement is made
in reliance solely upon its own judgment together with the advice of those advisors retained by Subscriber, if any.

 

    	2

     

    

 

4.4 Investment
Experience. Subscriber is an investor in securities of companies in the development stage and acknowledges that it is able to fend
for itself, can bear the economic risk of its investment and has such knowledge and experience in financial or business matters that
it is capable of evaluating the merits and risks of the investment in the Securities. Without limiting anything in this Section 4,
Subscriber acknowledges that materials and information that may have been presented by the Company and its representatives may have included
forward-looking statements, such as financial projections, business prospects and other such information, and that such information may
not be accurate. Subscriber acknowledges that the forward-looking statements involve a number of known and unknown risks and uncertainties
that may cause the Company’s actual results or outcome to be materially different from those anticipated and that may have been
presented to Subscriber. Such risks include the Company’s nascent stage, customer acceptance and actual demand, which may differ
significantly from expectations, the need for the Company to manage its growth, the need to raise funds for operations and other risks
within the Company’s industry. Market trends and external developments are subject to change beyond the control of the Company
and could materially adversely affect future results, business and operations. Subscriber has adequate means of providing for its current
needs, personal and family contingencies, and has no need for liquidity in the investment contemplated hereby. Subscriber is familiar
with the nature and extent of the risks inherent in investments in unregistered securities and has determined, either personally or in
consultation with Subscriber’s purchaser representative or attorney, that an investment in the Company is consistent with Subscriber’s
investment objectives and income prospects. Subscriber understands that the Company has incurred losses to date; that the Company may
need to obtain additional capital through debt and/or equity financing to implement its business plan; and that there can be no assurance
that such financing will be obtained or will be obtained on terms that are acceptable to the Company. Subscriber acknowledges and understands
that there can be no assurance that the Company will be able to operate profitably in the future. Subscriber acknowledges and understands
that the Company has not paid any distributions on its equity since its inception and, by reason of its present financial status and
its contemplated financial requirements, does not contemplate or anticipate paying any distributions upon its equity in the foreseeable
future.

 

4.5 Accredited
Investor. Subscriber is an “accredited investor” within the meaning of Rule 501 of Regulation D of the Securities and
Exchange Commission, as presently in effect.

 

4.6 Restricted
Securities. Subscriber understands that the Securities are characterized as “restricted securities” under the federal
securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under
such laws and applicable regulations such securities may be resold without registration under the Securities Act only in certain limited
circumstances.

 

5. Limitations
on Disposition. Subscriber’s rights under this Agreement and/or any of the Notes shall not be transferable without prior written
consent from the Company. Notwithstanding the foregoing, such consent shall not be required for the transfer of this Note to an Affiliate
of Subscriber, provided that notice of such transfer is provided to the Company and such Affiliate agrees to be bound by all of the terms
and conditions of this Agreement and the Note(s) being transferred on the same basis as applicable to the transferring Subscriber.

 

    	3

     

    

 

6. Information
Rights. The Company shall provide to each holder of a Note (or any Conversion Securities), as soon as practicable, (i) unaudited
annual financial statements and (ii) unaudited biannual financial statements. The Company shall further provide to each holder of a Note
copies of all information that is provided to the Company’s shareholders.

 

7.
Legends. It is understood that the Notes may bear the following legend:

 

“THIS NOTE AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, NOR UNDER ANY STATE SECURITIES LAW AND MAY NOT BE PLEDGED, SOLD, ASSIGNED OR TRANSFERRED UNLESS (i) A REGISTRATION STATEMENT WITH RESPECT THERETO IS EFFECTIVE UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND ANY APPLICABLE STATE SECURITIES LAW REGISTRATION REQUIREMENTS HAVE BEEN MET OR (ii) EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE REGISTRATION OR QUALIFICATION REQUIREMENTS OF APPLICABLE STATE SECURITIES LAW ARE AVAILABLE.”

 

8. Company
Covenant; Use of Proceeds. The Company hereby covenants and agrees that it may not incur any additional debt or other indebtedness
without approval of holders of at least 50% of the aggregate outstanding principal amount of all Similar Notes (a “Majority
in Interest”), except for (i) bona fide third-party debt from commercial lenders and equipment or capital lease financing and
(ii) other ordinary course trade credits.

 

The
Company shall use the proceeds of sale and issuance of the Notes to pursue the Company’s business plans, including, without limitation,
working capital needed for the operations of its business.

 

9. Miscellaneous.

 

9.1 Successors
and Assigns. The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors
and permitted assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than
the parties hereto or their respective successors and assigns any rights, remedies, obligations or liabilities under or by reason of
this Agreement, except as expressly provided in this Agreement.

 

9.2 Governing
Law. This Note shall be governed by the laws of the State of Delaware, without regard to the conflict of laws provisions thereof.

 

    	4

     

    

 

9.3 Jurisdiction;
Venue; Waiver of Jury Trial. Any controversy or claim, action, suit or proceeding arising out of or relating to this Agreement or
the Notes shall be brought in a State court in Cook County, Illinois or, if it has or can acquire jurisdiction, any Federal court located
in such State and County, and EACH OF THE PARTIES HERETO, AFTER CONSULTING WITH OR HAVING HAD THE OPPORTUNITY TO CONSULT WITH COUNSEL,
HEREBY KNOWINGLY, VOLUNTARILY, INTENTIONALLY AND IRREVOCABLY SUBMITS TO THE EXCLUSIVE PERSONAL JURISDICTION OF SUCH COURTS AND WAIVES
TRIAL BY JURY, IN EACH CASE IN CONNECTION WITH ANY CONTROVERSY, CLAIM, ACTION, SUIT OR PROCEEDING ARISING OUT OF OR RELATING TO THIS
NOTE. Each of the parties hereto hereby irrevocably and unconditionally waives any objection to the laying of venue of any controversy,
claim, action, suit or proceeding arising out of or relating to the Agreement, the Notes, or the transactions contemplated hereby or
thereby, in the courts of the State of Illinois or the United States of America, in each case located in Cook County, and hereby further
irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such matter brought in any such court
has been brought in an inconvenient forum. Each party hereby irrevocably waives personal service of process and consents to process being
served in any such controversy, claim, suit, action or proceeding by mailing a copy thereof to such party at the address for such notices
to it under this Note and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing
contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law.

 

9.4 Counterparts.
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic
signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart
so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

9.5 Titles
and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing
or interpreting this Agreement.

 

9.6 Notices.
All notices and other communications given or made pursuant hereto shall be in writing and shall be deemed effectively given if given
in accordance with the notice provisions set forth in Subscriber’s Note.

 

9.7 Finder’s
Fee; Fees and Expenses. Each party represents that it neither is nor will be obligated for any finder’s fee or commission in
connection with this transaction. Each party shall bear its own fees and expenses incurred in connection with this Agreement and the
Notes.

 

9.8 Entire
Agreement; Amendments and Waivers. This Agreement, the Notes and the other documents delivered pursuant hereto constitute the full
and entire understanding and agreement between the parties with regard to the subjects hereof and thereof. The Company’s agreements
with each Subscriber are separate agreements, and the sales of the Notes to each Subscriber are separate sales. Nonetheless, any term
of this Agreement or the Notes may be amended and the observance of any term of this Agreement or the Notes may be waived (either generally
or in a particular instance and either retroactively or prospectively), with the written consent of the Company and a Majority in Interest
subject to Section 9.9 hereof. Any waiver or amendment effected in accordance with this Section shall be binding upon each party
to this Agreement and any holder of any Note purchased under this Agreement at the time outstanding and each future holder of all such
Notes.

 

    	5

     

    

 

9.9 Effect
of Amendment or Waiver. As a condition of entering into this Agreement and purchasing any Note(s), Subscriber acknowledges that by
the operation of this Section 9.9 hereof, a Majority in Interest will have the right and power to diminish or eliminate all rights
of Subscriber under this Agreement and each Note issued to Subscriber; provided, however, that a Majority in Interest may not, without
Subscriber’s consent, reduce the amount of the outstanding principal under Subscriber’s Note, reduce the accrued and unpaid
interest under the Note or reduce the prepayment fee with respect to prepayment of the Note.

 

9.10 Severability.
If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision shall be excluded from
this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in
accordance with its terms.

 

9.11 Further
Assurances. From time to time, each of the parties hereto shall execute and deliver such additional documents and shall provide such
additional information as may be reasonably required to carry out the terms of this Agreement and the Notes and any agreements executed
in connection herewith or therewith.

 

9.12 Representations
and Warranties of the Company. The Company hereby makes the representations and warranties to each Subscriber as set forth on Schedule
9.12 attached hereto and made a part hereof.

 

9.13 Confidentiality.
Each Subscriber agrees not to disclose the terms of this Agreement or the Notes or the existence of such terms to anyone other than such
Subscriber’s financial advisors and legal counsel and officers or directors (if applicable).

 

[Signature
Page Follows]

 

    	6

     

    

 

NOTE
PURCHASE AGREEMENT SIGNATURE PAGE

 

Manner
in Which Title is to be Held (check one)

 

___Individual
Ownership

___Community
Property

___Joint
Tenant with Right of Survivorship (both parties must sign)

  x   Partnership

___Tenants
in common

___Corporation

___Trust

___Other
(please indicate)

 

	Dated:	01/31/2019	 	 

 

	SUBSCRIBER	 
	Company
                                            (if applicable):

    
	 
	Echo
    Venture, LLC	 
		

    $
    75,000.00

    

	 	Principal
    Amount of Initial Note(s)
	 	 
	 	$

    

	 	Principal
    Amount of Subsequent Note(s)

 

	By:
	/s/ Kristopher Kehler	 	 

	Signature	 	 	 
	Name:	Kristopher Kehler	 	 
	Title (if applicable): Managing Member	 	 

 

    	S-1

     

    

 

The
foregoing Purchase is accepted and the Company hereby agrees to be bound by its terms.

 

	 	 	BIOLIFE4D
    CORPORATION
	 	 	 
	 	By:	/s/ Steven Morris
	 	Name:	 Steven Morris
	 	 	 
	 	Date:	01/31/2019

 

    	S-2

     

    

 

EXHIBIT
A

 

FORM
OF CONVERTIBLE PROMISSORY NOTE

 

[see
attached]

 

    	S-3

     

    

 

THIS
CONVERTIBLE PROMISSORY NOTE (THIS “NOTE”) AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, NOR UNDER ANY STATE SECURITIES LAW AND MAY NOT BE PLEDGED, SOLD, ASSIGNED OR TRANSFERRED
UNLESS (i) A REGISTRATION STATEMENT WITH RESPECT THERETO IS EFFECTIVE UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND ANY APPLICABLE
STATE SECURITIES LAW REGISTRATION REQUIREMENTS HAVE BEEN MET OR (ii) EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS UNDER THE SECURITIES
ACT OF 1933, AS AMENDED, AND THE REGISTRATION OR QUALIFICATION REQUIREMENTS OF APPLICABLE STATE SECURITIES LAW ARE AVAILABLE.

 

BIOLIFE4D
CORPORATION

 

CONVERTIBLE
PROMISSORY NOTE (JANUARY 2019)

_________
__, 2019

 

1. Principal.
BioLife4D Corporation, a Delaware corporation (the “Company”), promises to pay to the order of ___________________________
(the “Holder”), the principal amount of $____________ on, _______________, 2022 (the “Maturity Date”);
provided, however, that the Company may extend the Maturity Date, in its sole and absolute discretion, to _______________, 2024 (the
“Extended Maturity Date”). The principal amount of this Note shall have been funded to the Company by the Holder on
or before the date of this Note. This Note is issued as part of a series of similar convertible promissory notes (each a “Similar
Note”) pursuant to the terms of that certain Note Purchase Agreement (January 2019), dated as of the date hereof (the “Note
Agreement”). Any securities into which the Outstanding Amount (as defined below) is converted are referred to as “Conversion
Securities.”

 

2. Interest.
The Company promises to pay simple, non-compounding interest, on the basis of a 365-day year, on the outstanding principal amount of
this Note at a rate per annum equal to: (i) 8.0%, from the date of this Note until the Maturity Date and (ii) 12.0%, from the Maturity
Date until the Extended Maturity Date.

 

3. Repayment
of Principal and Interest; Prepayment; Subordinated Debt. Except as set forth below in this Section 3, all unpaid and unconverted
principal and interest on this Note (the “Outstanding Amount”) shall be due and payable on the Maturity Date or the
Extended Maturity Date if the Company extends the Maturity Date pursuant to Section 1. The Company may prepay, in whole, at its
sole option and at any time prior to the Maturity Date or the Extended Maturity Date if the Company extends the Maturity Date pursuant
to Section 1 (the “Applicable Maturity Date”), the Outstanding Amount; provided, however, that (i) if the Company
prepays during the period beginning on the date hereof and ending on the one-year anniversary of the date hereof, then the Company shall
pay a prepayment fee in an amount equal to 30% of the Outstanding Amount and (ii) if the Company prepays during the period beginning
on the day after the one-year anniversary of the date hereof and ending on the two-year anniversary of the date hereof, then the Company
shall pay a prepayment fee in an amount equal to 20% of the Outstanding Amount.

 

    	 

     

    

 

4. Automatic
Conversion on Qualified Financing. If, prior to the Applicable Maturity Date, the Company completes a financing (which may occur
at one or more closings) in which it sells equity securities with an aggregate sales price of at least $7,500,000 (excluding amounts
converted under the Note or Similar Notes) for the principal purpose of raising capital (a “Qualified Financing”),
the Outstanding Amount will automatically convert (the “Qualified Financing Conversion”) into a number of securities
issued at the closing(s) of such Qualified Financing (such securities, the “New Equity”) determined by dividing the
Outstanding Amount by 80% of the price per share of the New Equity. Notwithstanding the foregoing, the Company shall have the right,
but not the obligation, to pay all accrued and unpaid interest under the Note prior to any conversion to New Equity in accordance with
Section 3 above. The Qualified Financing Conversion will occur concurrently with the funding of the Qualified Financing which causes
the financing to meet or exceed the threshold amount for a Qualified Financing. At the closing of a Qualified Financing, the Holder shall,
as reasonably requested by the Company, execute and deliver the same type of documentation as that executed and delivered by the investor(s)
in the Qualified Financing transaction.

 

5. Optional
Conversion. Prior the one-year anniversary of the date hereof, the Holder may, at its option, elect to convert the Outstanding Amount
into a number of shares of common stock of the Company (such shares, the “Existing Equity”) determined by dividing
the Outstanding Amount by 80% of the then-current price per share of the Existing Equity (the “Optional Conversion”).
In order to convert this Note into the Existing Equity, the Holder shall deliver to the Company written notice of the Holder’s
exercise of its option to convert this Note into Existing Equity.

 

6. Conversion
Mechanics. Upon any conversion of this Note into Conversion Securities, the Holder will deliver this Note to the Company for cancellation,
and the Company will deliver to the Holder a certificate or certificates representing the appropriate number of shares, as the case may
be, or other appropriate evidence of Conversion Securities. The Holder shall execute and deliver documentation reasonably requested by
the Company to effectuate the conversion. Conversion Securities shall not be issued in fractional shares upon any conversion effected
pursuant to this Note. The Company shall deliver cash in lieu of any fractional shares.

 

7. Representations
and Warranties of the Company. The Company represents and warrants to the Holder that the execution, delivery and performance by
the Company of this Note have been duly authorized by all necessary actions on the part of the Company and that the Company has the power
and authority to enter into and perform its obligations under this Note.

 

8. Representations
and Warranties of the Holder. The Holder represents and warrants to the Company as follows:

 

(a) Securities
Law Compliance. The Holder understands and acknowledges that both this Note and any securities into which this Note may be converted
have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state securities
laws and cannot be resold unless they are registered under the Securities Act and applicable state securities laws or an exemption from
such registration requirements is available. Accordingly, the Holder understands that the Note and such securities must be held by the
Holder indefinitely. The Holder is purchasing the Note for its own account for investment. The Holder has such knowledge and experience
in financial and business matters that such Holder is capable of evaluating the merits and risks of such investment, is able to incur
a complete loss of such investment and is able to bear the economic risk of such investment for an indefinite period of time. The Holder
is an accredited investor as such term is defined in Rule 501 of Regulation D under the Securities Act.

 

    	2

     

    

 

(b) Access
to Information. The Holder acknowledges that the Company has made its officers and representatives available for interview by the Holder
and has furnished the Holder with all documents and other information requested by the Holder. The Holder acknowledges that the Company
makes no representations or warranties with respect to any projections of the Company’s future operations or financial results.
The Holder acknowledges that any business plans prepared by the Company are subject to change and that any projections included in such
business plans are speculative in nature and it can be expected that some or all of the assumptions underlying the projections will not
materialize or will vary significantly from actual results.

 

(c) Confidentiality.
The Holder agrees to keep confidential any materials provided to the Holder by the Company in connection with the issuance, holding or
conversion of this Note.

 

9. Acceleration.
The Outstanding Amount shall become immediately due and payable in full without any action on the part of the Holder if the Company (i)
files for bankruptcy or receivership or is the subject of any involuntary proceeding under any such law, or (ii) defaults in its performance
of any agreement or covenant under the Note Agreement or this Note.

 

10. Replacement
Note. If this Note is lost or destroyed, the Company will issue a replacement Note upon receipt of an indemnity or other assurance
reasonably requested by the Company to protect it from any loss that it may suffer by reason of such replacement or subsequent presentment
of the original Note.

 

11. Notices;
Delivery. All notices or other communications required or permitted under this Note shall be in writing and mailed, emailed or delivered
to each party as follows: (a) if to the Holder, to the address set forth on the signature page hereof, or at such other address or email
address as the Holder furnishes the Company in writing, or (b) if to the Company, to BioLife4D Corporation, 250 Parkway Drive Suite 150
Lincolnshire, IL 60069, Attention: Steven Morris, email address: smorris@biolife4d.com with a copy to Horwood Marcus & Berk Chartered,
500 W. Madison, Suite 3700, Chicago, Illinois 60661, Attention: Jeffrey A. Hechtman, Esq., email address: jhechtma@hmblaw.com, or at
such other address or email address as the Company or the Company’s attorney, as the case may be, furnishes to the Holder in writing.
All such notices and communications will be deemed effectively given the earlier of (i) when received, (ii) when delivered personally,
(iii) one business day after being deposited with an overnight courier service of recognized standing, (iv) when delivered by email (with
receipt of appropriate confirmation) or (v) three days after being deposited in the U.S. mail, first class with postage prepaid.

 

12. Waiver.
The Company waives presentment, demand for performance, notice of non-performance, protest, notice of protest and notice of dishonor.

 

    	3

     

    

 

13. Non-Waiver.
The Holder’s failure to enforce or exercise any right or remedy provided in this Note shall not be construed as waiving the right
to enforce or exercise such or any other right or remedy at any later date.

 

14. Governing
Law. This Note shall be governed by the laws of the State of Illinois, without regard to the conflict of laws provisions thereof.

 

15. Jurisdiction;
Venue; Waiver of Jury Trial. Any controversy or claim, action, suit or proceeding arising out of or relating to this Note shall be
brought in a State court in Cook County, Illinois or, if it has or can acquire jurisdiction, any Federal court located in such State
and County, and EACH OF THE PARTIES HERETO, AFTER CONSULTING WITH OR HAVING HAD THE OPPORTUNITY TO CONSULT WITH COUNSEL, HEREBY KNOWINGLY,
VOLUNTARILY, INTENTIONALLY AND IRREVOCABLY SUBMITS TO THE EXCLUSIVE PERSONAL JURISDICTION OF SUCH COURTS AND WAIVES TRIAL BY JURY, IN
EACH CASE IN CONNECTION WITH ANY CONTROVERSY, CLAIM, ACTION, SUIT OR PROCEEDING ARISING OUT OF OR RELATING TO THIS NOTE. Each of the
parties hereto hereby irrevocably and unconditionally waives any objection to the laying of venue of any controversy, claim, action,
suit or proceeding arising out of or relating to this Note, or the transactions contemplated hereby, in the courts of the State of Illinois
or the United States of America, in each case located in Cook County, and hereby further irrevocably and unconditionally waives and agrees
not to plead or claim in any such court that any such matter brought in any such court has been brought in an inconvenient forum. Each
party hereby irrevocably waives personal service of process and consents to process being served in any such controversy, claim, suit,
action or proceeding by mailing a copy thereof to such party at the address for such notices to it under this Note and agrees that such
service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit
in any way any right to serve process in any manner permitted by law.

 

16. Amendments.
This Note may be amended only with the written consent of the Company and holders of more than 50% of the aggregate outstanding principal
amount of all Similar Notes (a “Majority in Interest”).

 

17. Severability.
If any provision of this Note shall for any reason be invalid, illegal or unenforceable, such provision shall not affect any other provision
of this Note, and the remaining provisions of this Note shall remain in full force and effect.

 

18. Assignment.
The Company’s obligations under this Note may not be assigned without the consent of a Majority in Interest. The Holder may not
assign, pledge or otherwise transfer its rights, remedies, obligations or liabilities under this Note without the prior written consent
of the Company. Subject to the foregoing, the rights and obligations of the Company and the Holder shall be binding upon and inure to
the benefit of the successors, assigns, heirs, administrators and permitted transferees of the parties.

 

19. Counterparts.
This Note may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute
one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature
complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered
shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

[Signature
page follows]

 

    	4

     

    

 

IN WITNESS WHEREOF, this Convertible Promissory Note has been executed on the date set forth above.

 

	 	COMPANY:
	 	 
	 	BIOLIFE4D
    CORPORATION
	 	 	 
	 	By:	/s/
    Steven Morris
	 	Its:	CEO

 

    	5

     

    

 

SCHEDULE
9.12

COMPANY
REPRESENTATIONS AND WARRANTIES

 

Representations
and Warranties of the Company. In connection with that certain Note Purchase Agreement (January 2019) to which this Schedule 9.12
is attached and incorporated into (this “Agreement”), the Company hereby represents and warrants to Subscriber that,
except as set forth on the disclosure schedule attached hereto, the following representations are true and complete (Capitalized terms
not otherwise defined in this Schedule 9.12 shall have the meanings ascribed to them in this Agreement.):

 

1.1. Organization,
Good Standing, Organizational Power and Qualification. The Company is a corporation, duly organized, validly existing and in good
standing under the laws of the State of Delaware and has all requisite organizational power and authority to carry on its business as
presently conducted and as proposed to be conducted and enter into the transactions contemplated herein. The Company is duly qualified
to transact business and is in good standing in each jurisdiction in which it conducts business except for those jurisdictions in which
failure to do so would not have a material adverse effect on the Company or its business.

 

1.2. Authorization.
All organizational action on the part of the Company, its stockholders, directors and officers, necessary for the authorization of this
Agreement, the Notes and all documents executed in connection therewith, including the reservation of the equity securities issuable
upon conversion of the Notes (collectively, “Transaction Documents”) and the execution, delivery and performance of
all obligations of the Company under the Transaction Documents, including the issuance and delivery of the Notes and the reservation
of the equity securities issuable upon conversion of the Notes (collectively, the “Conversion Securities”) will be
taken prior to the issuance of such Conversion Securities. The Transaction Documents, when executed and delivered by the Company, shall
constitute valid and binding obligations of the Company enforceable in accordance with their terms, subject to laws of general application
relating to bankruptcy, insolvency, the relief of debtors and, with respect to rights to indemnity, subject to federal and state securities
laws. The Conversion Securities, when issued in compliance with the provisions of the Transaction Documents will be validly issued, fully
paid and non-assessable and free of any liens or encumbrances and issued in compliance with all applicable federal and securities laws.

 

1.3. Capitalization.

 

(a) All
of the outstanding shares of common stock of the Company have been duly authorized, fully paid and non-assessable and was issued in compliance
with all applicable federal and state securities laws.

 

(b) Other
than as set forth in Schedule 1.3, there are no outstanding options, warrants, rights (including conversion or preemptive rights
and rights of first refusal or similar rights) or agreements, orally or in writing, to purchase or acquire from the Company any shares
of common stock of the Company, or any securities convertible into or exchangeable for shares of common stock of the Company.

 

    	 

     

    

 

1.4. Governmental
Consents and Filings. Assuming the accuracy of the representations made by the Subscriber in Section 4 of this Agreement,
no consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal,
state or local governmental authority is required on the part of the Company in connection with the valid execution and delivery of this
Agreement, the offer, sale or issuance of the Notes and the Conversion Securities issuable upon conversion of the Notes or the consummation
of any other transaction contemplated hereby.

 

1.5. Compliance
with Laws. To its knowledge, the Company is not in violation of any applicable statute, rule, regulation, order or restriction of
any domestic or foreign government or any instrumentality or agency thereof in respect of the conduct of its business or the ownership
of its properties, which violation would materially and adversely affect the business, assets, liabilities, financial condition or operations
of the Company.

 

1.6. Compliance
with Other Instruments. To its knowledge, the Company is not in violation or default of any term of its Certificate of Incorporation,
Bylaws, or of any provision of any mortgage, indenture or contract to which it is a party and by which it is bound or of any judgment,
decree, order or writ, other than such violations that would not individually or in the aggregate have a material adverse effect on the
Company. The execution, delivery and performance of the Transaction Documents, and the consummation of the transactions contemplated
by the Transaction Documents will not result in any such violation or be in conflict with, or constitute, with or without the passage
of time and giving of notice, either a default under any such provision, instrument, judgment, decree, order or writ or an event that
results in the creation of any lien, charge or encumbrance upon any assets of the Company or the suspension, revocation, impairment,
forfeiture, or nonrenewal of any material permit, license, authorization or approval applicable to the Company, its business or operations
or any of its assets or properties.

 

1.7. Offering.
Assuming the accuracy of the representations and warranties of the Subscriber contained in Section 4 of this Agreement, the offer,
issue, and sale of the Notes and the Conversion Securities (collectively, the “Securities”) are and will be exempt
from the registration and prospectus delivery requirements of the Securities Act of 1933, as amended (the “Act”), and have
been registered or qualified (or are exempt from registration and qualification) under the registration, permit, or qualification requirements
of all applicable state securities laws.

 

1.8. Litigation.
There is no claim, action, suit, proceeding, arbitration, complaint, charge or investigation pending or to the Company’s knowledge,
currently threatened in writing against the Company or any stockholder, director, officer or key employee of the Company arising out
of their employment or board relationship with the Company. Neither the Company nor, to the Company’s knowledge, any of its stockholders,
directors, officers or key employees is a party or is named as subject to the provisions of any order, writ, injunction, judgment or
decree of any court or government agency or instrumentality.

 

1.9. Property.
The property and assets that the Company owns are free and clear of all mortgages, deeds of trust, liens, loans and encumbrances, except
for statutory liens for the payment of current taxes that are not yet delinquent and encumbrances and liens that arise in the ordinary
course of business and do not materially impair the Company’s ownership or use of such property or assets. With respect to the
property and assets it leases, the Company is in compliance with such leases and, to its knowledge, holds a valid leasehold interest
free of any liens, claims or encumbrances other than those of the lessors of such property or assets. The Company does not own any real
property.

 

1.10. Material
Liabilities. The Company has no liability or obligation, absolute or contingent (individually or in the aggregate), except obligations
and liabilities already listed in its financial statements. The Company has no secured liabilities or obligations. All of the Company’s
liabilities and obligations for indebtedness including, but not limited to liabilities and obligations for indebtedness due to Steven
Morris and his affiliates, are unsecured and will be pari passu with the Notes.

 

1.11. Insurance.
The Company has in full force and effect insurance policies with extended coverage, sufficient in amount (subject to reasonable deductions)
to allow it to replace any of its properties that might be damaged or destroyed.

 

1.12. Permits.
The Company has all permits, licenses and any similar authority necessary for the conduct of its business, the lack of which could reasonably
be expected to have a material adverse effect on the Company. The Company is not in default in any material respect under any of such
permits, licenses or other similar authority.

 

    	2

     

    

 

DISCLOSURE
SCHEDULE

 

    	3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}]]